Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

POPRACH Alexandr LAKOMÝ Radek BORTLÍČEK Zbyněk MELICHAR Bohuslav PAVLÍK Tomáš SLABÝ Ondřej VYZULA Rostislav SVOBODA Marek KISS Igor STUDENTOVA Hana ZEMANOVA Milada FIALA Ondrej KUBACKOVA Katerina DUŠEK Ladislav HORNOVA Jana BUCHLER Tomas

Year of publication 2016
Type Article in Periodical
Magazine / Source Drugs & Aging
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1007/s40266-016-0390-1
Field Pharmacology and pharmaceutical chemistry
Keywords INTERFERON-ALPHA; SAFETY; CANCER
Description Background Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study was to analyse efficacy and toxicity of sunitinib as the first-line targeted therapy of elderly mRCC patients. Patients and Methods The national RENal information system registry of mRCC patients treated with targeted agents in the Czech Republic was used as the data source. Of the 1315 patients treated with sunitinib as first-line targeted therapy, 1016 and 299 patients were aged < 70 and aeyen70 years, respectively. Results Elderly patients had a significantly longer interval from diagnosis to the initiation of therapy. Median progression-free survival was 10.8 months (95 % confidence interval 9.8-11.8) and 8.8 months (7.2-10.4) for patients aged < 70 and aeyen70 years, respectively (p = 0.321). Median overall survival was 31.9 months (27.9-35.9) and 26.3 months (21.3-31.2), respectively (p = 0.044). Significantly more elderly patients started on a reduced dose of sunitinib or discontinued the treatment prior to progression because of adverse events. Conclusions The differences in patient profile and dose-reduction rates point to a different approach in the management of older and younger patients in daily clinical practice. The lower dose intensity of sunitinib in the elderly population may have translated into inferior survival.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.